Cory Berkland

Cory Berkland is the Mark and Becky Ruhmann Levin Professor in Biomedical Engineering at Washington University in St. Louis, affiliated with the McKelvey School of Engineering. His research focuses on pharmaceuticals, biomaterials, and molecular design for therapeutic applications.

• PhD, University of Illinois (2003)
• MS, University of Illinois (2001)
• BS, Iowa State University (1998)

Research interests include advanced materials for biomedical applications, regenerative engineering, and immune system therapeutics. His lab develops biomaterials and drug formulations to address unmet clinical needs, such as treatments for Type 1 diabetes. He has co-founded multiple companies, including Orbis Biosciences, Savara Pharmaceuticals, and Bond Biosciences, and currently serves as CEO of Bond Biosciences. He also holds executive roles at Kinimmune and Axioforce.

Recent research highlighted grants include a $2.6M grant from the Helmsley Trust for preclinical diabetes research (2024). His work bridges academia and industry, emphasizing translational medicine.

• Labs: Cory Berkland Lab (website linked)
• Start-ups: Orbis Biosciences, Savara Pharmaceuticals, Bond Biosciences